Home > Boards > US OTC > Biotechs > Revance Therapeutics, Inc. (RVNC)

hyperhidrosis - a friend of mine treats patients

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
rwwine Member Profile
 
Followed By 4
Posts 570
Boards Moderated 0
Alias Born 10/27/03
160x600 placeholder
Revance to Participate in Upcoming Virtual Healthcare Conferences Business Wire - 5/26/2021 4:05:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/26/2021 8:04:50 AM
Revance Provides Update on DaxibotulinumtoxinA for Injection Pre-Approval Inspection Business Wire - 5/26/2021 8:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/10/2021 4:42:24 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/10/2021 4:11:10 PM
Revance Therapeutics EPS beats by $0.11, beats on revenue Seeking Alpha - 5/10/2021 4:10:14 PM
Revance Reports First Quarter 2021 Financial Results, Provides Corporate Update Business Wire - 5/10/2021 4:05:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/7/2021 7:15:57 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/7/2021 7:13:32 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/7/2021 7:11:22 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/7/2021 7:09:36 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/7/2021 7:07:11 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/7/2021 7:04:54 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/7/2021 4:07:04 PM
Revance to Release First Quarter 2021 Financial Results on Monday, May 10, 2021 Business Wire - 5/3/2021 8:00:00 AM
Revance to Showcase Clinical Findings at The Aesthetic Meeting 2021 that Supports DaxibotulinumtoxinA’s 24-Week Long Durati... Business Wire - 4/27/2021 4:05:00 PM
Enrollment underway in Revance Therapeutics' late-stage DaxibotulinumtoxinA study Seeking Alpha - 4/27/2021 8:35:27 AM
Revance Announces First Patient Enrolled for DaxibotulinumtoxinA in Glabellar Lines & Cervical Dystonia in China by Fosun Pha... Business Wire - 4/27/2021 8:00:00 AM
Revance to Present Data on DaxibotulinumtoxinA for Injection & Hyaluronic Acid Fillers at American Academy of Dermatology VMX... Business Wire - 4/23/2021 8:00:00 AM
Revance signs supply agreement with contract manufacturer Lyophilization Seeking Alpha - 4/12/2021 4:32:25 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/6/2021 7:42:27 PM
Revance to Participate in the 20th Annual Needham Virtual Healthcare Conference Business Wire - 4/6/2021 4:05:00 PM
Revance to Showcase Phase 3 Results Evaluating DaxibotulinumtoxinA for Injection for the Treatment of Cervical Dystonia at th... Business Wire - 4/1/2021 8:00:00 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 3/24/2021 5:25:49 PM
Fortune Names Revance to the Top 10 Best Workplaces in Biopharma in 2021 Business Wire - 3/22/2021 4:05:00 PM
rwwine   Friday, 03/12/21 02:25:08 PM
Re: None
Post # of 1932 
hyperhidrosis - a friend of mine treats patients with 100 units of Botox for this indication (armpit treatment). Apparently health insurance in some cases cover the treatment. Maybe an opportunity down the road for RVNC.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences